SanegeneBio Announces $1.5B+ Strategic RNAi Drug Development Collaboration with Genentech
SANEGENEBIO
Small Nucleic Acid Drug Developer
On February 2, Yuanhe Holdings' invested company—Suzhou SANEGENEBIO Co., Ltd. (hereinafter referred to as "SANEGENEBIO") announced a global research and development collaboration and licensing agreement with Genentech (a subsidiary of Roche Group). Both parties will jointly advance the development of an RNAi therapy based on SANEGENEBIO's proprietary RNAi drug discovery platform.
According to the agreement, SANEGENEBIO will grant Genentech the global exclusive rights for the development and commercialization of the drug. SANEGENEBIO will be responsible for the early-stage research and development of the drug, while Genentech will take charge of all subsequent clinical development and commercialization activities.
SANEGENEBIO's proprietary RNAi drug development platform encompasses novel drug chemical modification and delivery technologies, which can be used to develop potentially groundbreaking siRNA drugs for multiple disease areas.
Under the terms of the agreement, SANEGENEBIO will receive an upfront payment of $200 million and is entitled to collect development and sales milestone payments totaling $1.5 billion, as well as tiered royalties.
SANEGENEBIO, founded in 2021, is a globally integrated clinical-stage biotechnology company focusing on the development of RNAi therapies. Relying on its proprietary GalNAc liver delivery platform and the industry-leading LEAD™ extrahepatic delivery platform, the company is committed to addressing significant unmet clinical needs in the fields of obesity, cardiometabolic diseases, and immune-mediated disorders. The LEAD™ platform can efficiently deliver siRNA specifically to extrahepatic tissues such as fat, muscle, immune cells, and the central nervous system, achieving efficient, safe, and long-lasting silencing of disease-causing genes while significantly reducing the dosing frequency. To date, SANEGENEBIO has initiated clinical trials for five drug candidates under research and is dedicated to developing innovative therapies with "Best-In-Class" and "First-In-Class" potential based on its RNAi drug development platform.